<DOC>
	<DOCNO>NCT03032484</DOCNO>
	<brief_summary>Randomized phase 2 study TVB-2640 combination Bevacizumab versus Bevacizumab alone .</brief_summary>
	<brief_title>TVB- 2640 Combination With Bevacizumab Patients With First Relapse High Grade Astrocytoma</brief_title>
	<detailed_description>Eligible patient randomize 2 separate arm : - Arm number one receive Bevacizumab every 2 week combination TVB-2640 day 1 day 28 first cycle . - Arm number two receive Bevacizumab alone every 2 week , day 1 15 first day 28 first cycle . - MR-Spectroscopy obtained patient ( arm ) day 28 first cycle . - Starting cycle 2 day 1 , patient converge single arm continue receive bevacizumab every 2 week combination TVB-2640 . Every cycle last 28 day .</detailed_description>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>At least 18 year age Ability understand purpose risk study sign write informed consent form approve investigator 's IRB/Ethics Committee Histologically confirm highgrade astrocytoma Progression follow standard combine modality treatment radiation temozolomide chemotherapy Recovered reversible toxicity prior therapy Grade 0 Grade 1 ECOG Pperformance Status 0 2 Life expectancy least 3 month Adequate renal liver function : AST/ALT ≤ 3 x ULN , Bilirubin ≤ 1.5 time ULN , Creatinine ≤ ULN Adequate hematologic status ( without hematologic support ) : Hemoglobin ≥ 9 g/dL , ANC ≥ 1500 cells/ml , Platelets ≥ 100,000 cells/ml All woman childbearing potential must negative serum pregnancy test male female subject must agree use effective mean contraception ( example , surgical sterilization use barrier contraception either condom diaphragm conjunction spermicidal gel IUD ) partner entry study six month last dose . Receiving warfarin ( coumarin derivative ) unable switch low molecular weight heparin ( LMWH ) first dose study drug Evidence acute intracranial intratumoral hemorrhage either MRI CT scan . Subjects resolve hemorrhage change punctuate hemorrhage , hemosiderine eligible Unable undergo MRI scan ( e.g. , pacemaker ) Received enzymeinducing antiepileptic agent within 14 day study drug ( e.g. , carbamazepine , phenytoin , phenobarbital , primidone ) Not recover NCI CTCAE v.4.03 Grade ≤ 1 AEs ( except alopecia lymphopenia ) due surgery , antineoplastic agent , investigational drug , medication administer prior study drug Evidence wind dehiscence Pregnant breastfeeding Clinically significant Dry Eye necessary contact lens use Serious intercurrent illness : Hypertension ( two blood pressure reading perform screen &gt; 150 mmHg systolic &gt; 100 mmHg diastolic ) despite optimal treatment , Nonhealing wound ulcer , Uncontrolled life threaten cardiac arrhythmia , Untreated hypothyroidism , Uncontrolled active infection , Symptomatic congestive heart failure unstable angina pectoris within 3 month prior study drug , Gastrointestinal perforation , abdominal fistula , intraabdominal abscess within 1 year Inherited bleeding diathesis coagulopathy risk bleed HIV , Hepatitis B C document infection Received follow prior anticancer therapy : Nonstandard radiation therapy brachytherapy , systemic radioisotope therapy ( RIT ) , intraoperative radiotherapy ( IORT ) . Note : stereotactic radiosurgery ( SRS ) allow , Nonantiangiogenic therapy ( include investigational agent small molecular kinase inhibitor ) within 7 day 5 halflives , whichever short , prior first dose study drug , Biologic agent ( antibody , immune modulators , vaccine , cytokine ) within 21 day prior first dose study drug , Nitrosoureas mitomycin C within 42 day metronomic/protracted</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>